company background image
DARE logo

Daré Bioscience NasdaqCM:DARE Stock Report

Last Price

US$0.43

Market Cap

US$42.4m

7D

25.5%

1Y

-58.6%

Updated

27 Feb, 2024

Data

Company Financials +

Daré Bioscience, Inc.

NasdaqCM:DARE Stock Report

Market Cap: US$42.4m

DARE Stock Overview

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women’s health in the United States.

DARE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Daré Bioscience, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Daré Bioscience
Historical stock prices
Current Share PriceUS$0.43
52 Week HighUS$1.15
52 Week LowUS$0.27
Beta1.03
1 Month Change22.19%
3 Month Change22.89%
1 Year Change-58.64%
3 Year Change-77.24%
5 Year Change-49.99%
Change since IPO-92.83%

Recent News & Updates

Recent updates

We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

Nov 07
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Jul 21
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Mar 12
Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Oct 17

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Oct 10

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Aug 29

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Jun 30

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Apr 02
Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Diving Back Into Daré Bioscience Again

Jan 07

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Nov 26
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study

Apr 26

Diving Into Daré Bioscience

Jan 31

Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dec 22
Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dare Bioscience EPS misses by $0.06

Nov 12

Shareholder Returns

DAREUS PharmaceuticalsUS Market
7D25.5%1.7%1.8%
1Y-58.6%26.4%25.1%

Return vs Industry: DARE underperformed the US Pharmaceuticals industry which returned 24% over the past year.

Return vs Market: DARE underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is DARE's price volatile compared to industry and market?
DARE volatility
DARE Average Weekly Movement15.0%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: DARE's share price has been volatile over the past 3 months.

Volatility Over Time: DARE's weekly volatility has increased from 9% to 15% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200528Sabrina Johnsonhttps://www.darebioscience.com

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women’s health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company’s product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Daré Bioscience, Inc. Fundamentals Summary

How do Daré Bioscience's earnings and revenue compare to its market cap?
DARE fundamental statistics
Market capUS$42.39m
Earnings (TTM)-US$41.05m
Revenue (TTM)US$1.00m

42.4x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DARE income statement (TTM)
RevenueUS$1.00m
Cost of RevenueUS$100.00k
Gross ProfitUS$900.00k
Other ExpensesUS$41.95m
Earnings-US$41.05m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin90.00%
Net Profit Margin-4,104.71%
Debt/Equity Ratio0%

How did DARE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.